Key Points
- Twist Bioscience CEO Emily Leproust sold 1,610 shares on April 21 at an average price of $65.01 for about $104,666, a transaction disclosed to the SEC and executed under a pre‑arranged Rule 10b5‑1 trading plan.
- After the sale Leproust still directly owns 858,887 shares (roughly $55.8M), representing only a 0.19% reduction in her stake.
- TWST has a market cap of $3.61B and a 12‑month range of $23.30–$66.06; the company remains unprofitable (negative EPS and margins) despite 16.9% YoY revenue growth, and the stock carries an average analyst rating of Moderate Buy with a $47.13 target.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 1,610 shares of the company's stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $65.01, for a total value of $104,666.10. Following the completion of the sale, the chief executive officer directly owned 858,887 shares in the company, valued at approximately $55,836,243.87. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Twist Bioscience Stock Performance
Shares of TWST stock opened at $58.85 on Friday. The company's fifty day moving average price is $49.71 and its 200-day moving average price is $39.96. The stock has a market cap of $3.61 billion, a PE ratio of -45.98 and a beta of 2.20. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $66.06.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million for the quarter, compared to analysts' expectations of $100.32 million. Twist Bioscience's quarterly revenue was up 16.9% on a year-over-year basis. On average, equities analysts expect that Twist Bioscience Corporation will post -1.86 EPS for the current fiscal year.
Wall Street Analyst Weigh In
TWST has been the subject of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research note on Friday, March 27th. Robert W. Baird set a $50.00 price target on Twist Bioscience in a report on Tuesday, February 3rd. Barclays lifted their price target on Twist Bioscience from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 14th. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Evercore raised their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $47.13.
Get Our Latest Stock Analysis on TWST
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Campbell & CO Investment Adviser LLC lifted its stake in Twist Bioscience by 227.6% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company's stock valued at $1,328,000 after acquiring an additional 32,792 shares during the period. Thrivent Financial for Lutherans lifted its position in Twist Bioscience by 14.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company's stock valued at $41,171,000 after purchasing an additional 184,726 shares during the period. EdgePoint Investment Group Inc. boosted its holdings in Twist Bioscience by 71.1% in the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company's stock worth $114,876,000 after purchasing an additional 1,696,377 shares during the last quarter. Baillie Gifford & Co. grew its position in Twist Bioscience by 62.8% in the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company's stock worth $35,533,000 after purchasing an additional 487,052 shares during the period. Finally, First Light Asset Management LLC raised its stake in Twist Bioscience by 26.4% during the 3rd quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company's stock valued at $33,624,000 after buying an additional 249,850 shares during the last quarter.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
